Please try another search
Nextgen Biomed Ltd is an Israel-based research and development company. Its main activity is to own EyePen product. The Company's product is dedicated to people with diabetes and consists of an injection module which allows to monitor the doses and time of insulin intake. The EyePen mobile app keeps diabetes management systematic by monitoring behavior and provides alerts for human errors such as forgetting a pen, double insulin injections, or skipping injections.
Name | Age | Since | Title |
---|---|---|---|
Ephraim Itzkowitz | 73 | 2020 | Director |
Abraham Noth | 62 | 2020 | Director |
Uri Zenko | - | 2019 | CEO & Director |
Yaakov Amidror | 73 | 2021 | Chairman of the Board |
Hedan Orenshtein | 42 | 2013 | Independent Director |
Colette Avital | 82 | 2020 | Independent External Director |
Shulam Lapidot | 42 | 2020 | Director |
Sagit Sabag | 37 | 2020 | Independent External Director |
Yaniv Hevron | 44 | 2020 | CEO & Director |
Ilana Eldan | 43 | 2022 | Director |
Alon Pinkas | 62 | 2022 | Director |
Jacob Kaul | 73 | 2022 | Director |
Tom Shabat | 34 | 2022 | Independent External Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review